Email: cspc@cspc.cn
News
January 20, 2025
Share:
Previous: SYS6017 (HERPES ZOSTER mRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL
Next: SYS6043 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us